Equities
Health CareMedical Equipment and Services
  • Price (USD)345.87
  • Today's Change-3.69 / -1.06%
  • Shares traded137.93k
  • 1 Year change-26.57%
  • Beta0.8737
Data delayed at least 15 minutes, as of Mar 28 2024 20:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Its Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes and food testing regimes. The Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are primarily sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

  • Revenue in USD (TTM)2.67bn
  • Net income in USD-637.32m
  • Incorporated1975
  • Employees8.03k
  • Location
    Bio Rad Laboratories Inc1000 ALFRED NOBEL DRHERCULES 94547-1811United StatesUSA
  • Phone+1 (510) 724-7000
  • Fax+1 (510) 741-5817
  • Websitehttps://www.bio-rad.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
OSI Systems, Inc.1.37bn113.62m2.41bn6.24k21.493.1215.771.766.586.5879.2945.290.85652.183.95218,997.907.126.2311.639.1835.6135.698.317.070.79577.250.37230.008.043.25-20.4347.89-6.71--
Mirion Technologies Inc800.90m-96.90m2.57bn3.00k--1.7340.173.21-0.4993-0.49934.086.570.29353.093.62266,966.70-3.62---4.10--44.50---12.32--1.48-0.16910.3068--11.58--65.01------
Integra Lifesciences Holdings Corp1.54bn67.74m2.72bn3.95k41.251.7114.241.770.84440.844419.1920.310.40191.595.79390,667.301.773.331.923.6863.0963.674.397.992.187.950.48570.00-1.030.9219-62.482.19-2.97--
Olink Holding AB (publ) - ADR169.60m-31.60m2.93bn707.00------17.30-0.2547-0.25471.36--0.31450.99632.94239,882.60-5.86---6.40--67.49---18.63--3.55--0.0506--21.27---145.90------
Badger Meter Inc703.59m92.60m4.73bn2.14k51.229.1539.156.723.143.1423.8917.601.073.128.79328,781.3014.0312.2617.1814.6039.2939.3813.1612.062.19--0.0036.3624.4010.1639.2527.226.7912.07
Vontier Corp3.10bn376.90m6.89bn8.00k18.517.7513.722.222.422.4219.845.770.71675.186.12386,900.008.7310.8011.1814.0446.2444.6212.1813.361.085.800.71942.24-2.803.03-6.08-0.50187.23--
Cognex Corp837.55m113.23m7.30bn2.99k65.104.8454.028.710.65250.65254.838.770.42131.666.67279,928.805.7010.636.2311.5671.7972.9713.5222.383.40--0.0057.03-16.750.7624-47.46-13.24-9.069.03
MKS Instruments Inc3.62bn-1.84bn8.85bn10.00k--3.57--2.44-27.56-27.5654.1736.950.35132.015.19362,100.00-17.86-1.60-19.57-1.7545.3544.95-50.84-3.252.011.160.6596--2.1111.78-652.85--6.692.44
Bio Rad Laboratories Inc2.67bn-637.32m9.88bn8.03k--1.14--3.70-21.49-21.4991.24306.510.20711.655.43332,660.30-4.949.08-5.169.6053.5655.55-23.8641.974.340.30950.12070.00-4.673.1382.43--3.83--
Bruker Corp2.96bn427.20m12.92bn9.71k32.289.8923.874.362.912.9120.149.490.75421.646.15305,398.2010.858.3814.9911.4051.1749.8514.3911.390.994829.030.47569.8117.149.3644.0318.9116.794.56
Revvity Inc2.75bn179.50m13.02bn11.50k73.161.6521.304.731.445.5022.0363.790.19862.914.42239,180.101.304.761.455.3955.9857.196.5315.341.774.070.33136.52-16.95-0.1982-64.99-5.28-2.690.00
Avantor Inc6.97bn321.10m17.35bn14.50k54.073.3023.982.490.47310.473110.287.760.52715.295.88480,496.602.432.972.763.3533.9333.444.615.061.053.190.51320.00-7.263.51-51.52--31.17--
Data as of Mar 28 2024. Currency figures normalised to Bio Rad Laboratories Inc's reporting currency: US Dollar USD

Institutional shareholders

33.44%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 29 Feb 20242.43m10.36%
Veritas Asset Management LLPas of 31 Dec 20231.08m4.62%
BlackRock Fund Advisorsas of 31 Dec 20231.00m4.29%
SSgA Funds Management, Inc.as of 31 Dec 2023874.91k3.74%
Geode Capital Management LLCas of 31 Dec 2023460.09k1.96%
AllianceBernstein LPas of 31 Dec 2023441.70k1.89%
Invesco Capital Management LLCas of 31 Dec 2023409.74k1.75%
EARNEST Partners LLCas of 31 Dec 2023393.63k1.68%
Managed Account Advisors LLCas of 31 Dec 2023374.14k1.60%
Southeastern Asset Management, Inc.as of 31 Dec 2023364.06k1.55%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.